A Phase 1 interventional study of PF-06463922 and rifampin in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-25.
Sponsored by Pfizer · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to estimate the effect of rifampin on the single dose PK of PF-06463922.
This will be a Phase 1, open-label, 2-period, 2-treatment, fixed-sequence, cross-over study in approximately 12 healthy subjects employing administration of a single oral dose of PF-06463922 in the fasted state alone, and with multiple dosing of rifampin 600 mg once a day to estimate the effect of multiple dose rifampin on the single dose PK of PF-06463922.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subjects will receive a 100 mg single oral dose of PF-06463922 followed by a 100 mg single dose of PF-06463922 combined with 600 mg QD dose of rifampin with at least 10 days of washout period between two PF-06463922 doses.
Drug: PF-06463922 · Drug: rifampin
100 mg oral dose on day 1 in period 1 and on day 8 in period 2
Also known as: lorlatinib
600 mg QD from day 1 to day 12 in period 2.
Also known as: rifampicin
Plasma AUCinf for PF-06463922 Given Alone and With Rifampin
AUCinf is the plasma area under the plasma concentration-time profile from time 0 extrapolated to infinite time. The pharmacokinetics (PK) parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma Cmax for PF-06463922 Given Alone and With Rifampin
Cmax is the maximum observed plasma concentration. PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma AUClast for PF-06463922 Given Alone and With Rifampin
AUClast is the plasma area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma Tmax for PF-06463922 Given Alone and With Rifampin
Tmax is the time for maximum observed plasma concentration (Cmax). The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma t1/2 for PF-06463922 Given Alone and With Rifampin
Terminal plasma half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half. The PK parameter analysis population is defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma CL/F for PF-06463922 Given Alone and With Rifampin
CL/F is the apparent oral clearance. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma Vz/F for PF-06463922 Given Alone and With Rifampin
Vz/F is the apparent volume of distribution (only after single dose).The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg administration with rifampin in Period 2.
Plasma AUClast for PF-06895751 When PF-06463922 Given Alone and With Rifampin
AUClast was the plasma area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma AUCinf for PF-06895751 When PF-06463922 Given Alone and With Rifampin
AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma Tmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin.
Tmax was the time for maximum observed plasma concentration (Cmax). The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma t1/2 for PF-06895751 When PF-06463922 Given Alone and With Rifampin
T1/2 was the terminal plasma half-life. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma Cmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin
Cmax was the maximum observed plasma concentration. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for Cmax (MRCmax) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin
Cmax was the maximum observed plasma concentration of PF-06463922 and PF-06895751 ( metabolite of PF-06463922). The molecular weight adjusted metabolite/parent ratio (PF-06895751/PF-06463922) for Cmax was presented. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUClast (MRAUClast) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin
AUClast was the plasma area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration of PF-06463922 and PF-06895751 ( metabolite of PF-06463922). The molecular weight adjusted metabolite/parent ratio (PF-06895751/PF-06463922) for AUClast was presented. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUCinf (MRAUCinf) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin
AUCinf was the plasma area under the plasma concentration-time profile from time 0 extrapolated to infinite time of PF-06463922 and PF-06895751 ( metabolite of PF-06463922). The molecular weight adjusted metabolite/parent ratio (PF-06895751/PF-06463922) for AUCinf was presented. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 12, 24, 36, 48, 60, 72, 96, 120 hours postdose on Day 1 after PF-06463922 100 mg administration in Period 1, and at the same time points on Day 8 after PF-06463922 100 mg with rifampin administration in Period 2.
Number of Participants With End of Study Abnormal Laboratory Findings Meeting the Criteria of Potentially Significant Clinical Concern
The total number of participants with laboratory test abnormalities was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis and some other tests (including follicle-simulating hormone\[FSH\], urine drug screening, hepatitis B surface antigen \[HBsAg\], hepatitis B core antibody \[HBcAb\], hepatitis C virus antibody \[HCVAb\] and human immunodeficiency virus \[HIV\]. Clinical significance was judged by the investigator.
Time frame: Baseline to about 18 days after the first PF-06463922 dose
Number of Participants With Physical Examination Findings Meeting the Criteria of Potentially Significant Clinical Concern
A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Clinical significance was judged by the investigator.
Time frame: Baseline to about 18 days after the first PF-06463922 dose.
Number of Participants With Changes From Baseline and Absolute Values in Vital Signs Meeting the Criteria of Potentially Significant Clinical Concerns
Criteria for potentially clinically important changes in vital signs were defined as: supine and standing systolic blood pressure (SBP) of less than (\<90) millimeters of mercury (mm Hg) or change in supine and standing SBP more than or equal to (\>=) 30 mm Hg; supine and standing diastolic blood pressure (DBP) of \< 50 mm Hg or change in supine and standing DBP of \>= 20 mm Hg; supine and standing pulse rate of \< 40 or \>120 beats per minute (bpm). Figure "99999" signifies data not measurable/applicable. Maximum Decrease is abbreviated as Max.Dec., and Maximum Increase is abbreviated as Max.Inc. n is the number of participants contributing to the parameter, not applicable is abbreviated as N/A.
Time frame: Baseline to about 18 days after the first PF-06463922 dose.
Number of Participants With Electrocardiogram (ECG) Findings Meeting the Criteria of Potentially Significant Clinical Concerns
PR interval was the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization. Criteria for potentially clinically important changes (chg) in ECG were defined as: absolute values of PR interval \>=200 to \<220 msec, \>=220 to \<240 msec, \>=240 to \<260 msec and \>=260 msec. Increase from baseline \>=40, \<60, \>=60 and \<80, \>=80, and relative change from baseline \>25%. The beginning of the Q wave to the end of the T wave corresponding to electrical systole (QT) interval corrected using the Fridericia formular (QTCF) of 450 to \<480 msec, 480 to \<500 msec and \>=500 msec, or an increase of 30 to \<60 msec of \>=60 msec. Maximum is abbreviated as Max.
Time frame: Baseline to about 18 days after the first PF-06463922 dose.
Number of Participants With Concomitant Treatments Meeting the Criteria of Potentially Significant Clinical Concerns
Participants abstained from all concomitant treatments, except for the treatment of adverse events. Limited use of non-prescription medications that were not believed to affect participant safety or the overall results of the study might be permitted on a case by case basis following approval by the sponsor. All participants were questioned about concomitant treatment at each clinic visit. Treatments taken within 28 days before the first dose of study investigational product were documented as a prior treatment. Treatment taken after the first dose of study investigational product were documented as concomitant treatments. Females taking hormone replacement therapy might be eligible to participate in this study if they were willing to discontinue therapy at least 28 days prior to the first dose of study treatment and remained off hormonal therapy for duration of the study. Clinical significance was judged by the investigator.
Time frame: Baseline to about 18 days after the first PF-06463922 dose.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causalities and Treatment-Related)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a casual relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: 1) resulted in death; 2) was life threatening (immediate risk of death); 3) required inpatient hospitalization or prolongation of existing hospitalization; 4) resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); 5) resulted in congenital anomaly/birth defect. TEAE included both non-serious adverse events and serious adverse events.
Time frame: Baseline to about 18 days after the first PF-06463922 dose.
| Milestone | PF-06463922 100 mg Single Dose (SD) | Rifampin 600 Once a Day (QD) + PF-06463922 100 mg SD |
|---|---|---|
| Started | 12 | 0 |
| Completed | 12 | 0 |
| Not completed | 0 | 0 |
| Milestone | PF-06463922 100 mg Single Dose (SD) | Rifampin 600 Once a Day (QD) + PF-06463922 100 mg SD |
|---|---|---|
| Started | 12 | 0 |
| Completed | 12 | 0 |
| Not completed | 0 | 0 |
| Milestone | PF-06463922 100 mg Single Dose (SD) | Rifampin 600 Once a Day (QD) + PF-06463922 100 mg SD |
|---|---|---|
| Started | 0 | 12 |
| Completed | 0 | 11 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
AUCinf is the plasma area under the plasma concentration-time profile from time 0 extrapolated to infinite time. The pharmacokinetics (PK) parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
| nanogram (ng)*hr/ millilitre (mL) | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma AUCinf for PF-06463922 Given Alone and With Rifampin | 8766 ± 19 | 1299 ± 30 |
Cmax is the maximum observed plasma concentration. PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
| ng/mL | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma Cmax for PF-06463922 Given Alone and With Rifampin | 621.4 ± 26 | 148.4 ± 31 |
AUClast is the plasma area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
| ng•hr/mL | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma AUClast for PF-06463922 Given Alone and With Rifampin | 8597 ± 19 | 1200 ± 32 |
Tmax is the time for maximum observed plasma concentration (Cmax). The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
| hr | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma Tmax for PF-06463922 Given Alone and With Rifampin | 1.50 (0.683 to 2.00) | 1.51 (1.00 to 4.00) |
Terminal plasma half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half. The PK parameter analysis population is defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
| hr | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma t1/2 for PF-06463922 Given Alone and With Rifampin | 21.22 ± 4.12 | 10.16 ± 2.43 |
CL/F is the apparent oral clearance. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
| L/hr | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma CL/F for PF-06463922 Given Alone and With Rifampin | 11.39 ± 20 | 76.91 ± 30 |
Vz/F is the apparent volume of distribution (only after single dose).The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
| liter | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma Vz/F for PF-06463922 Given Alone and With Rifampin | 342.6 ± 19 | 1095 ± 47 |
AUClast was the plasma area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.
| ng*hr/mL | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma AUClast for PF-06895751 When PF-06463922 Given Alone and With Rifampin | 4105 ± 33 | 3169 ± 60 |
AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.
| ng•hr/mL | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma AUCinf for PF-06895751 When PF-06463922 Given Alone and With Rifampin | 4453 ± 38 | 3291 ± 60 |
Tmax was the time for maximum observed plasma concentration (Cmax). The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.
| hr | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma Tmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin. | 30.1 (24.0 to 36.1) | 12.0 (6.00 to 36.1) |
T1/2 was the terminal plasma half-life. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.
| hr | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma t1/2 for PF-06895751 When PF-06463922 Given Alone and With Rifampin | 29.14 ± 7.54 | 18.43 ± 4.10 |
Cmax was the maximum observed plasma concentration. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.
| ng/mL | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma Cmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin | 59.02 ± 29 | 76.45 ± 38 |
Cmax was the maximum observed plasma concentration of PF-06463922 and PF-06895751 ( metabolite of PF-06463922). The molecular weight adjusted metabolite/parent ratio (PF-06895751/PF-06463922) for Cmax was presented. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
| ratio | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for Cmax (MRCmax) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin | 0.2094 ± 29 | 1.136 ± 35 |
AUClast was the plasma area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration of PF-06463922 and PF-06895751 ( metabolite of PF-06463922). The molecular weight adjusted metabolite/parent ratio (PF-06895751/PF-06463922) for AUClast was presented. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period. PF-06895751 was the metabolite of PF-06463922.
| ratio | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUClast (MRAUClast) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin | 1.053 ± 24 | 5.831 ± 56 |
AUCinf was the plasma area under the plasma concentration-time profile from time 0 extrapolated to infinite time of PF-06463922 and PF-06895751 ( metabolite of PF-06463922). The molecular weight adjusted metabolite/parent ratio (PF-06895751/PF-06463922) for AUCinf was presented. The PK parameter analysis population was defined as all participants enrolled and treated who have at least 1 of the PF-06463922 PK parameters of primary interest in at least 1 treatment period.
| ratio | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUCinf (MRAUCinf) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin | 1.166 ± 25 | 5.521 ± 56 |
The total number of participants with laboratory test abnormalities was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis and some other tests (including follicle-simulating hormone\[FSH\], urine drug screening, hepatitis B surface antigen \[HBsAg\], hepatitis B core antibody \[HBcAb\], hepatitis C virus antibody \[HCVAb\] and human immunodeficiency virus \[HIV\]. Clinical significance was judged by the investigator.
| Participants | PF-06463922 100 mg | Rifampin 600 mg QD | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|---|
| No. of Participants Evaluable for Lab. Abnormality | 12 | 12 | 12 |
| No. With Lab. Abnormalities | 5 | 6 | 11 |
A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Clinical significance was judged by the investigator.
| Participants | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Number of Participants With Physical Examination Findings Meeting the Criteria of Potentially Significant Clinical Concern | 0 | 0 |
Criteria for potentially clinically important changes in vital signs were defined as: supine and standing systolic blood pressure (SBP) of less than (\<90) millimeters of mercury (mm Hg) or change in supine and standing SBP more than or equal to (\>=) 30 mm Hg; supine and standing diastolic blood pressure (DBP) of \< 50 mm Hg or change in supine and standing DBP of \>= 20 mm Hg; supine and standing pulse rate of \< 40 or \>120 beats per minute (bpm). Figure "99999" signifies data not measurable/applicable. Maximum Decrease is abbreviated as Max.Dec., and Maximum Increase is abbreviated as Max.Inc. n is the number of participants contributing to the parameter, not applicable is abbreviated as N/A.
| Participants | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Supine SBP (mmHg) <90 | 0 | 1 |
| Standing SBP (mmHg) <90 | — | 0 |
| Supine DBP (mmHg) <50 | 0 | 0 |
| Standing DBP (mmHg) <50 | — | 0 |
| Supine PR (BPM) >120 | 0 | 0 |
| Supine PR (BPM) <40 | 0 | 0 |
| Standing PR (BPM) >120 | — | 0 |
| Standing PR (BPM) <40 | — | 0 |
| Max.Dec. From Baseline in Supine SBP (mm Hg) >=30 | 0 | 0 |
| Max.Dec. From Baseline in Supine DBP (mm Hg) >=20 | 0 | 0 |
| Max.Inc. From Baseline in Supine SBP (mm Hg) >=30 | 0 | 1 |
| Max.Inc. From Baseline in Supine DBP (mm Hg) >=20 | 0 | 0 |
PR interval was the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization. Criteria for potentially clinically important changes (chg) in ECG were defined as: absolute values of PR interval \>=200 to \<220 msec, \>=220 to \<240 msec, \>=240 to \<260 msec and \>=260 msec. Increase from baseline \>=40, \<60, \>=60 and \<80, \>=80, and relative change from baseline \>25%. The beginning of the Q wave to the end of the T wave corresponding to electrical systole (QT) interval corrected using the Fridericia formular (QTCF) of 450 to \<480 msec, 480 to \<500 msec and \>=500 msec, or an increase of 30 to \<60 msec of \>=60 msec. Maximum is abbreviated as Max.
| Participants | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Maximum (Max) PR Interval (msec) 200-<220 | 0 | 0 |
| Max PR Interval (msec) 220-<240 | 0 | 0 |
| Max PR Interval (msec) 240-<260 | 0 | 0 |
| Max PR Interval (msec) >=260 | 0 | 0 |
| Max QT Interval (msec) >=500 | 0 | 1 |
| Max QTCF Interval (msec) 450-<480 | 0 | 1 |
| Max QTCF Interval (msec) 480-<500 | 0 | 0 |
| Max QTCF Interval (msec) >=500 | 0 | 0 |
| Max PR Interval Inc. From Baseline (msec) 40-<60 | 0 | 0 |
| Max PR Interval Inc. From Baseline (msec) 60-<80 | 0 | 0 |
| Max PR Interval Inc. From Baseline (msec) >=80 | 0 | 0 |
| Max PR Interval Inc.From Baseline(msec)PctChg>25% | 0 | 0 |
| Max QTCF Inc. From Baseline (msec) 30<=Chg<60 | 0 | 1 |
| Max QTCF Inc. From Baseline (msec) Chg>=60 | 0 | 0 |
Participants abstained from all concomitant treatments, except for the treatment of adverse events. Limited use of non-prescription medications that were not believed to affect participant safety or the overall results of the study might be permitted on a case by case basis following approval by the sponsor. All participants were questioned about concomitant treatment at each clinic visit. Treatments taken within 28 days before the first dose of study investigational product were documented as a prior treatment. Treatment taken after the first dose of study investigational product were documented as concomitant treatments. Females taking hormone replacement therapy might be eligible to participate in this study if they were willing to discontinue therapy at least 28 days prior to the first dose of study treatment and remained off hormonal therapy for duration of the study. Clinical significance was judged by the investigator.
| Participants | PF-06463922 100 mg | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|
| Number of Participants With Concomitant Treatments Meeting the Criteria of Potentially Significant Clinical Concerns | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a casual relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: 1) resulted in death; 2) was life threatening (immediate risk of death); 3) required inpatient hospitalization or prolongation of existing hospitalization; 4) resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); 5) resulted in congenital anomaly/birth defect. TEAE included both non-serious adverse events and serious adverse events.
| Participants | PF-06463922 100 mg | Rifampin 600 mg QD | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|---|
| No. of Participants with AEs (all Causalities) | 1 | 5 | 12 |
| No. of Participants with SAEs (all Causalities) | 0 | 0 | 5 |
| Participants with Severe AEs (all Causalities) | 0 | 0 | 7 |
| Discontinued due to AEs (all Causality) | 0 | 0 | 12 |
| No. of Participants with AEs (Treatment Related) | 1 | 4 | 12 |
| No. of Participants with SAEs (Treatment Related) | 0 | 0 | 5 |
| Participants with Severe AEs (Treatment Related) | 0 | 0 | 7 |
| Discontinued due to AEs (Treatment Related) | 0 | 0 | 12 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-06463922 100 mg | — | 0/12 (0%) | 1/12 (8.3%) |
| Rifampin 600 mg QD | — | 0/12 (0%) | 5/12 (41.7%) |
| Rifampin 600 mg + PF-06463922 100 mg | — | 5/12 (41.7%) | 11/12 (91.7%) |
| Event | PF-06463922 100 mg | Rifampin 600 mg QD | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|---|
| Drug-induced liver injuryHepatobiliary disorders | 0/12 | 0/12 | 5/12 |
| Event | PF-06463922 100 mg | Rifampin 600 mg QD | Rifampin 600 mg + PF-06463922 100 mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 0/12 | 0/12 | 9/12 |
| Drug-induced liver injuryHepatobiliary disorders | 0/12 | 0/12 | 7/12 |
| VomitingGastrointestinal disorders | 0/12 | 0/12 | 3/12 |
| DizzinessNervous system disorders | 1/12 | 0/12 | 3/12 |
| DyspepsiaGastrointestinal disorders | 0/12 | 0/12 | 2/12 |
| Decreased appetiteMetabolism and nutrition disorders | 0/12 | 0/12 | 2/12 |
| Dry eyeEye disorders | 0/12 | 1/12 | 1/12 |
| PhotophobiaEye disorders | 0/12 | 1/12 | 1/12 |
| Abdominal painGastrointestinal disorders | 0/12 | 0/12 | 1/12 |
| Abdominal pain lowerGastrointestinal disorders | 0/12 | 0/12 | 1/12 |
| Age, Continuous(years) | Entire Study |
|---|---|
| Mean | 36.5 ± 11.1 |
| Sex: Female, Male(Participants) | Entire Study |
|---|---|
| Female | 1 |
| Male | 11 |
Ran from Jul 2016 to primary completion in Oct 2016, 3 months.
Results were first posted in Jan 2019, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lorlatinib